AAAAAA
Results: 1-25/29
Authors:
Schink, JC
Weller, E
Harris, LS
Cella, D
Gerstner, J
Falkson, C
Wadler, S
Citation: Jc. Schink et al., Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: An Eastern Cooperative Oncology Group phase II study (E2E93), CANCER J, 7(2), 2001, pp. 155-164
Authors:
Wadler, S
Citation: S. Wadler, New developments in the treatment of ovarian cancer, EXPERT OP I, 10(6), 2001, pp. 1167-1172
Authors:
Wang, CG
Fu, MF
Mani, S
Wadler, S
Senderowicz, AM
Pestell, RG
Citation: Cg. Wang et al., Histone acetylation and the cell-cycle in cancer, FRONT BIOSC, 6, 2001, pp. D610-D629
Authors:
Pivot, X
Wadler, S
Kelly, C
Ruxer, R
Tortochaux, J
Stern, J
Belpomme, D
Humblet, Y
Domenge, C
Clendeninn, N
Johnston, A
Penning, C
Schneider, M
Citation: X. Pivot et al., Result of two randomized trials comparing nolatrexed (Thymitaq (TM)) versus methotrexate in patients with recurrent head and neck cancer, ANN ONCOL, 12(11), 2001, pp. 1595-1599
Authors:
O'Dwyer, PJ
Manola, J
Valone, FH
Ryan, LM
Hines, JD
Wadler, S
Haller, DG
Arbuck, SG
Weiner, LM
Mayer, RJ
Benson, AB
Citation: Pj. O'Dwyer et al., Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study, J CL ONCOL, 19(9), 2001, pp. 2413-2421
Authors:
Markman, M
Bundy, BN
Alberts, DS
Fowler, JM
Clark-Pearson, DL
Carson, LF
Wadler, S
Sickel, J
Citation: M. Markman et al., Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel andintraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group, J CL ONCOL, 19(4), 2001, pp. 1001-1007
Authors:
Rothenberg, ML
Meropol, NJ
Poplin, EA
Van Cutsem, E
Wadler, S
Citation: Ml. Rothenberg et al., Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel, J CL ONCOL, 19(18), 2001, pp. 3801-3807
Authors:
Rajdev, L
Yu, ZF
Wadler, S
Weller, E
Kahn, SB
Tormey, D
Skeel, R
Wiernik, PH
Citation: L. Rajdev et al., N-Methylformamide in advanced squamous cancer of the uterine cervix: An Eastern Cooperative Oncology Group phase II trial, INV NEW DR, 19(3), 2001, pp. 233-237
Authors:
Augenlicht, LH
Wadler, S
Arango, D
Citation: Lh. Augenlicht et al., Clinical response to fluorouracil and p53, N ENG J MED, 345(14), 2001, pp. 1065-1066
Authors:
Lane, ME
Yu, B
Rice, A
Lipson, KE
Liang, C
Sun, L
Tang, C
McMahon, G
Pestell, RG
Wadler, S
Citation: Me. Lane et al., A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells, CANCER RES, 61(16), 2001, pp. 6170-6177
Authors:
Arango, D
Corner, GA
Wadler, S
Catalano, PJ
Augenlicht, LH
Citation: D. Arango et al., c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo, CANCER RES, 61(12), 2001, pp. 4910-4915
Authors:
Malik, UR
Makower, DF
Wadler, S
Citation: Ur. Malik et al., Interferon-mediated fatigue, CANCER, 92(6), 2001, pp. 1664-1668
Authors:
Andreyev, HJN
Norman, AR
Cunningham, D
Oates, J
Dix, BR
Iacopetta, BJ
Young, J
Walsh, T
Ward, R
Hawkins, N
Beranek, M
Jandik, P
Benamouzig, R
Jullian, E
Laurent-Puig, P
Olschwang, S
Muller, O
Hoffmann, I
Rabes, HM
Zietz, C
Troungos, C
Valavanis, C
Yuen, ST
Ho, JWC
Croke, CT
O'Donoghue, DP
Giaretti, W
Rapallo, A
Russo, A
Bazan, V
Tanaka, M
Omura, K
Azuma, T
Ohkusa, T
Fujimori, T
Ono, Y
Pauly, M
Faber, C
Glaesener, R
de Goeij, AFPM
Arends, JW
Andersen, SN
Lovig, T
Breivik, J
Gaudernack, G
Clausen, OPF
De Angelis, P
Meling, GI
Rognum, TO
Smith, R
Goh, HS
Font, A
Rosell, R
Sun, XF
Zhang, H
Benhattar, J
Losi, L
Lee, JQ
Wang, ST
Clarke, PA
Bell, S
Quirke, P
Bubb, VJ
Piris, J
Cruickshank, NR
Morton, D
Fox, JC
Al-Mulla, F
Lees, N
Hall, CN
Snary, D
Wilkinson, K
Dillon, D
Costa, J
Pricolo, VE
Finkelstein, SD
Thebo, JS
Senagore, AJ
Halter, SA
Wadler, S
Malik, S
Krtolica, K
Urosevic, N
Citation: Hjn. Andreyev et al., Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study, BR J CANC, 85(5), 2001, pp. 692-696
Authors:
Smith, RV
Kotz, T
Beitler, JJ
Wadler, S
Citation: Rv. Smith et al., Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea - Initial results, ARCH OTOLAR, 126(3), 2000, pp. 384-389
Authors:
Kornblau, S
Benson, AB
Catalano, R
Champlin, RE
Engelking, C
Field, M
Ippoliti, C
Lazarus, HM
Mitchell, E
Rubin, J
Stiff, PJ
Vokes, E
Wadler, S
Citation: S. Kornblau et al., Management of cancer treatment-related diarrhea: Issues and therapeutic strategies, J PAIN SYMP, 19(2), 2000, pp. 118-129
Authors:
Peeva, E
Fishman, AD
Goddard, G
Wadler, S
Barland, P
Citation: E. Peeva et al., Rheumatoid arthritis exacerbation caused by exogenous interleukin-12, ARTH RHEUM, 43(2), 2000, pp. 461-463
Authors:
Wadler, S
Citation: S. Wadler, Adjuvant therapy for colorectal cancers, STRATEGIES IN ADJUVANT THERAPY, 2000, pp. 19-39
Authors:
Mani, S
Gu, Y
Wadler, S
Fingert, H
Citation: S. Mani et al., Antisense therapeutics in oncology: Points to consider in their clinical evaluation, ANTISENSE N, 9(6), 1999, pp. 543-547
Authors:
Wadler, S
Schwartz, EL
Anderson, P
Runowicz, CD
Chuang, L
Del Priore, G
Hochster, H
Goldberg, G
Fields, A
Loewen, G
Haynes, H
Citation: S. Wadler et al., Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer, CA J SCI AM, 5(3), 1999, pp. 165-170
Authors:
Dabon-Almirante, CLM
Damle, S
Wadler, S
Hupart, K
Citation: Clm. Dabon-almirante et al., Related case report: In vivo suppression of thyrotropin by 9-cis retinoic acid, CA J SCI AM, 5(3), 1999, pp. 171-173
Authors:
Kotz, T
Abraham, S
Beitler, JJ
Wadler, S
Smith, RV
Citation: T. Kotz et al., Pharyngeal transport dysfunction consequent to an organ-sparing protocol, ARCH OTOLAR, 125(4), 1999, pp. 410-413
Authors:
Hochster, H
Wadler, S
Runowicz, C
Liebes, L
Cohen, H
Wallach, R
Sorich, J
Taubes, B
Speyer, J
Citation: H. Hochster et al., Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy, J CL ONCOL, 17(8), 1999, pp. 2553-2561
Authors:
Wadler, S
Damle, S
Haynes, H
Kaleya, R
Schechner, R
Berkenblit, R
Ladner, RD
Murgo, A
Citation: S. Wadler et al., Phase II pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract, J CL ONCOL, 17(6), 1999, pp. 1771-1778
Authors:
McGill, FM
Ritter, DB
Rickard, CS
Kaleya, RN
Wadler, S
Greston, WM
O'Hanlan, KA
Citation: Fm. Mcgill et al., Krukenberg tumors: Can management be improved?, GYNECOL OBS, 48(1), 1999, pp. 61-65
Authors:
Damle, S
Beitler, JJ
Haynes, H
Camacho, M
Wolf, E
Wadler, S
Citation: S. Damle et al., Phase I-II study of 5-fluorouracil, recombinant interferon alpha 2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus, AM J CL ONC, 22(4), 1999, pp. 391-395